The Relative Strength (RS) Rating for Supernus Pharmaceuticals jumped into a new percentile Thursday, with an increase from 78 to 81.
This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating north of 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Supernus Pharmaceuticals is still inside a buying range after clearing a 35.41 buy point in a cup with handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of a proper buy zone.
Supernus Pharmaceuticals showed 0% earnings growth last quarter. Revenue increased 14%.
The company holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
